Efficient Therapy of Inflammatory Bowel Disease (IBD) with Highly Specific and Durable Targeted Ta2C Modified with Chondroitin Sulfate (TACS)
Source abstract
Abstract
Abstract Non‐invasive localization of lesions and specific targeted therapy are still the main challenges for inflammatory bowel disease (IBD). Ta, as a medical metal element, has been widely used in the treatment of different diseases because of its excellent physicochemical properties but is still far from being explored in IBD. Here, Ta2C modified with chondroitin sulfate (CS) (TACS) is evaluated as a highly targeted therapy nanomedicine for IBD. Specifically, TACS is modified with dual targeting CS functions due to IBD lesion‐specific positive charges and high expression of CD44 receptors. Thanks to the acid stability, sensitive CT imaging function, and strong reactive oxygen species (ROS) elimination ability, oral TACS can accurately locate and delineate IBD lesions through non‐invasive CT imaging, and specifically targeted treat IBD effectively because high levels of ROS are a central factor in the progression of IBD. As expected, TACS has much better imaging and therapeutic effects than clinical CT contrast agent and first‐line drug 5‐aminosalicylic acid, respectively. The mechanism of TACS treatment mainly involves protection of mitochondria, elimination of oxidative stress, inhibiting macrophage M1 polarization, protection of intestinal barrier, and restoration of intestinal flora balance. Collectively, this work provides unprecedented opportunities for oral nanomedicines to targeted therapy of IBD.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Sarcoidosis and Beryllium Toxicity Research · Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Geriatric Surgery Xiangya Hospital Central South University Changsha 410008 China
Xiangya School of Pharmaceutical Sciences Central South University Changsha 410008 China
National Clinical Research Center for Geriatric Disorders Xiangya Hospital Central South University Changsha 410008 China
Department of General Surgery Xiangya Hospital Central South University Changsha 410008 China
Department of Pharmacy, Xiangya Hospital Central South University Changsha 410008 P. R. China
Hubei Key Laboratory of Optical Information and Pattern Recognition Wuhan Institute of Technology Wuhan 430205 China
Department of Radiology Xiangya Hospital Central South University Changsha 410008 China
Department of Pathology Xiangya Hospital, Central South University Changsha 410008 China
Hunan Provincial Key Laboratory of Cardiovascular Research Xiangya School of Pharmaceutical Sciences Central South University Changsha 410008 China
Geriatric Medical Center People's Hospital of Ningxia Hui Autonomous Region Yinchuan 750002 China
Key Laboratory of Aging‐related Bone and Joint Diseases Prevention and Treatment. Ministry of Education Xiangya Hospital Central South University Changsha 410008 China
Funding
National Natural Science Foundation of China
References (79)
Show source-provided references
1. GBD 2017 Inflammatory Bowel Disease Collaborators, Lancet Gastroenterol. Hepatol. · 2020 · 5 · 17
2. 10.1038/s41572-020-0156-210.1038/s41572-020-0156-2 ↗
3. 10.1038/s41572-020-0205-x10.1038/s41572-020-0205-x ↗
4. 10.1053/j.gastro.2021.12.24610.1053/j.gastro.2021.12.246 ↗
5. 10.1136/gutjnl-2021-32656210.1136/gutjnl-2021-326562 ↗
6. 10.1093/ecco-jcc/jjac09810.1093/ecco-jcc/jjac098 ↗
7. 10.1016/S2468-1253(21)00312-510.1016/S2468-1253(21)00312-5 ↗
8. 10.1016/S2468-1253(21)00377-010.1016/S2468-1253(21)00377-0 ↗
9. 10.1053/j.gastro.2018.06.04610.1053/j.gastro.2018.06.046 ↗
10. 10.1016/S2468-1253(22)00385-510.1016/S2468-1253(22)00385-5 ↗
11. 10.1053/j.gastro.2019.08.02710.1053/j.gastro.2019.08.027 ↗
12. 10.1016/S0140-6736(17)30570-610.1016/S0140-6736(17)30570-6 ↗
13. 10.1053/j.gastro.2020.01.04710.1053/j.gastro.2020.01.047 ↗
14. Kobayashi T. · Nat. Rev. Dis. Primers · 2023 · 20 · 79
15. 10.1016/j.redox.2023.10260310.1016/j.redox.2023.102603 ↗
16. 10.1152/physrev.00040.201210.1152/physrev.00040.2012 ↗
17. 10.1002/smll.20220735010.1002/smll.202207350 ↗
18. 10.1080/15548627.2019.163538410.1080/15548627.2019.1635384 ↗
19. 10.1186/s40824-022-00307-010.1186/s40824-022-00307-0 ↗
20. 10.1016/S0140-6736(95)91991-010.1016/S0140-6736(95)91991-0 ↗
21. 10.1126/scitranslmed.aaa565710.1126/scitranslmed.aaa5657 ↗
22. 10.1016/j.carbpol.2020.11710310.1016/j.carbpol.2020.117103 ↗
23. 10.1148/radiol.201817238110.1148/radiol.2018172381 ↗
24. 10.1186/s12951-023-01770-010.1186/s12951-023-01770-0 ↗
25. 10.1021/acsnano.0c0345710.1021/acsnano.0c03457 ↗
26. 10.1039/D1NH00626F10.1039/D1NH00626F ↗
27. 10.1002/adma.20211060810.1002/adma.202110608 ↗
28. 10.1002/adfm.20200469210.1002/adfm.202004692 ↗
29. 10.1016/j.carbpol.2016.05.10210.1016/j.carbpol.2016.05.102 ↗
30. 10.1016/j.ijbiomac.2013.10.02610.1016/j.ijbiomac.2013.10.026 ↗
31. 10.1016/j.carbpol.2012.04.06810.1016/j.carbpol.2012.04.068 ↗
32. 10.1002/adma.20210755410.1002/adma.202107554 ↗
33. 10.1039/D0CS00579G10.1039/D0CS00579G ↗
34. Atreya R. · Nat. Rev. Dis. Primers · 2021 · 18 · 544
35. 10.1021/jacs.7b0781810.1021/jacs.7b07818 ↗
36. 10.1021/acsnano.2c0463010.1021/acsnano.2c04630 ↗
37. 10.1038/s41572-023-00432-710.1038/s41572-023-00432-7 ↗
38. 10.1038/s41579-018-0036-x10.1038/s41579-018-0036-x ↗
39. Odenwald M. A. · Nat. Rev. Dis. Primers · 2017 · 14 · 9
40. 10.1038/s41586-019-0992-y10.1038/s41586-019-0992-y ↗
41. 10.1016/j.biomaterials.2019.05.01210.1016/j.biomaterials.2019.05.012 ↗
42. 10.1021/acsnano.0c0101810.1021/acsnano.0c01018 ↗
43. 10.1038/s41563-019-0462-910.1038/s41563-019-0462-9 ↗
44. 10.1146/annurev-physiol-060821-08330610.1146/annurev-physiol-060821-083306 ↗
45. 10.1016/j.jaci.2017.08.01710.1016/j.jaci.2017.08.017 ↗
46. 10.1034/j.1600-079X.2001.300101.x10.1034/j.1600-079X.2001.300101.x ↗
47. 10.1038/s41580-019-0173-810.1038/s41580-019-0173-8 ↗
48. 10.1038/nrd.2016.25310.1038/nrd.2016.253 ↗
49. 10.1053/j.gastro.2021.08.05510.1053/j.gastro.2021.08.055 ↗
50. 10.1038/nature1861010.1038/nature18610 ↗
51. 10.1146/annurev-pathmechdis-012419-03284710.1146/annurev-pathmechdis-012419-032847 ↗
52. 10.1182/blood-2005-09-369110.1182/blood-2005-09-3691 ↗
53. 10.1016/j.joca.2010.02.01710.1016/j.joca.2010.02.017 ↗
54. 10.1016/j.cell.2019.10.01510.1016/j.cell.2019.10.015 ↗
55. 10.1016/j.molmed.2023.01.00110.1016/j.molmed.2023.01.001 ↗
56. 10.1039/D1NH00315A10.1039/D1NH00315A ↗
57. Mehandru S. · Nat. Rev. Dis. Primers · 2021 · 18 · 83
58. 10.1053/j.gastro.2020.11.00810.1053/j.gastro.2020.11.008 ↗
59. 10.1016/j.jaci.2019.11.00310.1016/j.jaci.2019.11.003 ↗
60. Ni J. · Nat. Rev. Dis. Primers · 2017 · 14 · 573
61. 10.1186/s13059-021-02576-910.1186/s13059-021-02576-9 ↗
62. 10.3390/antiox1109167410.3390/antiox11091674 ↗
63. 10.1128/CMR.00060-1810.1128/CMR.00060-18 ↗
64. 10.3390/jcm1008174910.3390/jcm10081749 ↗
65. 10.1080/19490976.2018.156076710.1080/19490976.2018.1560767 ↗
66. 10.1053/j.gastro.2019.11.29410.1053/j.gastro.2019.11.294 ↗
67. 10.1038/ismej.2016.17610.1038/ismej.2016.176 ↗
68. 10.3389/fimmu.2022.93469510.3389/fimmu.2022.934695 ↗
69. 10.1053/j.gastro.2020.09.05610.1053/j.gastro.2020.09.056 ↗
70. 10.1021/acsnano.2c0555810.1021/acsnano.2c05558 ↗
71. 10.1038/s41467-020-20351-510.1038/s41467-020-20351-5 ↗
72. 10.1038/s43586-022-00174-y10.1038/s43586-022-00174-y ↗
73. 10.1021/ab500041d10.1021/ab500041d ↗
74. 10.1166/jbn.2018.257810.1166/jbn.2018.2578 ↗
75. 10.1039/C4NR06377E10.1039/C4NR06377E ↗
76. 10.3390/md1905028210.3390/md19050282 ↗
77. 10.1002/jbm.a.3630510.1002/jbm.a.36305 ↗
78. 10.1002/jbm.a.3703210.1002/jbm.a.37032 ↗
79. 10.1016/S1470-2045(19)30326-210.1016/S1470-2045(19)30326-2 ↗